These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17180691)

  • 21. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica.
    McConville M; Brennan GP; Flanagan A; Edgar HW; Hanna RE; McCoy M; Gordon AW; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2009 May; 162(1-2):75-88. PubMed ID: 19282108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
    Alvarez LI; Solana HD; Mottier ML; Virkel GL; Fairweather I; Lanusse CE
    Parasitology; 2005 Oct; 131(Pt 4):501-10. PubMed ID: 16174415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The netherlands.
    Moll L; Gaasenbeek CP; Vellema P; Borgsteede FH
    Vet Parasitol; 2000 Jul; 91(1-2):153-8. PubMed ID: 10889368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica.
    Toner E; Brennan GP; McConvery F; Meaney M; Fairweather I
    Parasitology; 2010 Apr; 137(5):855-70. PubMed ID: 20030907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2010 Jul; 107(2):337-53. PubMed ID: 20512589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole.
    Halferty L; Brennan GP; Hanna RE; Edgar HW; Meaney MM; McConville M; Trudgett A; Hoey L; Fairweather I
    Vet Parasitol; 2008 Aug; 155(1-2):49-58. PubMed ID: 18511199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fasciola hepatica: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology.
    Hanna RE; McMahon C; Ellison S; Edgar HW; Kajugu PE; Gordon A; Irwin D; Barley JP; Malone FE; Brennan GP; Fairweather I
    Vet Parasitol; 2015 Jan; 207(1-2):34-43. PubMed ID: 25529143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative assessment of albendazole and triclabendazole ovicidal activity on Fasciola hepatica eggs.
    Alvarez L; Moreno G; Moreno L; Ceballos L; Shaw L; Fairweather I; Lanusse C
    Vet Parasitol; 2009 Oct; 164(2-4):211-6. PubMed ID: 19560276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle.
    Hutchinson GW; Dawson K; Fitzgibbon CC; Martin PJ
    Vet Parasitol; 2009 Jun; 162(3-4):278-84. PubMed ID: 19375232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Vet Parasitol; 2010 Sep; 172(3-4):238-48. PubMed ID: 20627418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica.
    Stitt AW; Fairweather I
    Parasitology; 1994 Jun; 108 ( Pt 5)():555-67. PubMed ID: 8052511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-course and accumulation of triclabendazole and its metabolites in bile, liver tissues and flukes collected from treated sheep.
    Moreno L; Ceballos L; Fairweather I; Lanusse C; Alvarez L
    Exp Parasitol; 2014 Jan; 136():14-9. PubMed ID: 24211244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-dependent changes to the tegumental system and gastrodermis of adult Fasciola hepatica following treatment in vivo with triclabendazole in the sheep host.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Vet Parasitol; 2010 Dec; 174(3-4):218-27. PubMed ID: 20933333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitology; 2009 Feb; 136(2):183-92. PubMed ID: 19079818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex).
    Stitt AW; Fairweather I
    Parasitol Res; 1993; 79(7):529-36. PubMed ID: 8278333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica.
    Toner E; McConvery F; Brennan GP; Meaney M; Fairweather I
    Parasitology; 2009 Apr; 136(5):523-35. PubMed ID: 19272211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.
    Ceballos L; Moreno L; Alvarez L; Shaw L; Fairweather I; Lanusse C
    BMC Vet Res; 2010 Feb; 6():8. PubMed ID: 20128898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fasciola hepatica: histological demonstration of apoptosis in the reproductive organs of flukes of triclabendazole-sensitive and triclabendazole-resistant isolates, and in field-derived flukes from triclabendazole-treated hosts, using in situ hybridisation to visualise endonuclease-generated DNA strand breaks.
    Hanna RE; Forster FI; Brennan GP; Fairweather I
    Vet Parasitol; 2013 Jan; 191(3-4):240-51. PubMed ID: 23062689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect.
    Mottier L; Alvarez L; Fairweather I; Lanusse C
    J Parasitol; 2006 Dec; 92(6):1355-60. PubMed ID: 17304820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitology; 2010 Apr; 137(5):871-80. PubMed ID: 20025819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.